Sign in Subscribe
Scientists

Induction Chemotherapy Shows No Benefit in Unresectable Stage III Non-Small Cell Lung Cancer

Strategic Insights

— 1 min read

Recent research published in the Journal of Thoracic Oncology has demonstrated that induction chemotherapy before concurrent chemoradiotherapy has no significant benefit in improving survival rates for patients with unresectable Stage III non-small cell lung cancer. The study, conducted by Stinchcombe and colleagues, evaluated the effectiveness of induction chemotherapy in two prognostic groups of patients and found that it provided no survival advantage. The researchers used a Cox proportional hazard model to assess the impact of various factors, including hemoglobin levels, performance status, and weight loss, on survival outcomes.

Key Takeaways:

  • The study evaluated the effectiveness of induction chemotherapy in 398 patients with unresectable Stage III non-small cell lung cancer.
  • The researchers found no significant benefit from the addition of induction chemotherapy, with a hazard ratio of 0.86 (95% CI, 0.63-1.17; p = 0.34).
  • The study demonstrated no evidence that induction chemotherapy is beneficial in either prognostic group.
  • The researchers used a Cox proportional hazard model to assess the impact of various factors on survival outcomes, including hemoglobin levels, performance status, and weight loss.
  • Hemoglobin levels, performance status, and weight loss were found to be significant predictors of survival outcomes.
  • The study suggests that concurrent chemoradiotherapy alone may be sufficient for patients with unresectable Stage III non-small cell lung cancer.

Statistics:

  • 398 patients were enrolled in the study.
  • The hazard ratio for overall survival was 0.86 (95% CI, 0.63-1.17; p = 0.34).
  • Hemoglobin levels ≤ 13 g/dl were associated with a hazard ratio of 1.19 (95% CI, 0.77-1.85; p = 0.44).
  • Performance status (PS) 1 was associated with a hazard ratio of 1.29 (95% CI, 0.85-1.95; p = 0.24).
  • Weight loss ≥ 5% was associated with a hazard ratio of 1.41 (95% CI, 0.93-2.15; p = 0.10).

Sources:

  • Stinchcombe, T.E., et al. (2009). Treatment outcomes of different prognostic groups of patients on Cancer and Leukemia Group B trial 39801 induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer. Journal of Thoracic Oncology, 4(9), 1117-1125.
  • Journal of Thoracic Oncology. (2009). Treatment Outcomes of Different Prognostic Groups of Patients on Cancer and Leukemia Group B Trial 39801 Induction Chemotherapy Followed by Chemoradiotherapy Compared with Chemoradiotherapy Alone for Unresectable Stage III Non-small Cell Lung Cancer.

Read more